Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis - PubMed
4 hours ago
- #RSV vaccine
- #older adults
- #vaccine effectiveness
- RSV vaccine uptake among adults aged ≥60 years in the 2023/24 RSV season was 18.0% in the US, with variations across subgroups.
- Pooled vaccine effectiveness estimates for adults ≥60 years were 75.3% against any RSV-positive infection, 76.4% against RSV-related emergency visits, 74.8% against hospital admissions, and 79.8% against severe RSV-associated disease.
- Safety signals post-vaccination included Guillain-Barré syndrome (GBS), with rates between 5.2-6.5 cases per million doses for RSVPreF3+AS01 and 9.0-18.2 cases per million doses for RSVpreF vaccines.
- The study highlights low global RSV vaccine uptake among older adults but confirms a favorable safety profile and high effectiveness, advocating for wider vaccine implementation.
- The research was a systematic review and meta-analysis covering over 121.8 million individuals across multiple countries, with no funding received for the study.